CDCRX Mutual Fund

NAV$11.92

Fund Essentials - as of May 31, 2026

Net Assets
$5M
Expense Ratio
1.95%
Dividend Yield (Current)
9.83%
Holdings
68
Inception Date
Jan 5, 2012
Fund Family
Copeland Capital Management LLC
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+4.60%
1 Year+10.67%
3 Year+9.68%
5 Year+10.06%
10 Year+9.39%

Asset Allocation

Stocks: 99.92%
Cash: 0.07%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
LRCXLam Research Corpcommon Stock2.67%
AVGOBroadcom Inc2.64%
AAPLApple Inc2.63%
MSMorgan Stanley2.45%
WCCWesco International Inc2.36%
Top 10 Concentration: 24.13%Report Date: May 31, 2026
Download all 68 holdings for CDCRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
9.83%
Frequency
Annually
Latest Distribution
$1.64
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how CDCRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

CDCRX Mutual Fund Overview

CDCRX Mutual Fund (Copeland Dividend Growth Fund Class C) is managed by Copeland Capital Management LLC with $5.3M in net assets. CDCRX expense ratio is 1.95%, holding 68 positions across sectors including Information Technology, Industrials, Financials. Inception date: 2012-01-05.

CDCRX performance shows a YTD return of 4.60%. The 1-year return is 10.67% and the 5-year return is 10.06%. CDCRX dividend yield stands at 9.83%, paid annually.

CDCRX top holdings include Lam Research Corpcommon Stock (2.7%), Broadcom Inc (2.6%), Apple Inc (2.6%), Morgan Stanley (2.5%), Wesco International Inc (2.4%). View all CDCRX holdings, sector breakdown, or dividend history.

CDCRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. CDCRX alternatives are available via the screener, along with tax-loss harvesting opportunities.